Copyright
©The Author(s) 2015.
World J Hepatol. Dec 8, 2015; 7(28): 2819-2828
Published online Dec 8, 2015. doi: 10.4254/wjh.v7.i28.2819
Published online Dec 8, 2015. doi: 10.4254/wjh.v7.i28.2819
Table 1 Newer weight reduction drugs in pipeline
Drug | Mechanism of action |
Cetilistat | Gastrointestinal and pancreatic lipase inhibitor |
Velneperit | Neuropeptide Y5 receptor inhibitor, appetite suppression |
Tesofensine | Inhibition of serotonin, dopamine, and noradrenaline reuptake |
Metreleptin | Leptin receptor agonist |
Obinepitide | Dual neuropeptide Y2/Y4 receptor agonist |
Beloranib | MetAP2 inhibition |
- Citation: Kumar N, Choudhary NS. Treating morbid obesity in cirrhosis: A quest of holy grail. World J Hepatol 2015; 7(28): 2819-2828
- URL: https://www.wjgnet.com/1948-5182/full/v7/i28/2819.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i28.2819